Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Glioma 1Chondrosarcoma 1Cholangiocarcinoma 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1

Interventions

Doxorubicin 3temsirolimus 1resiquimod 1poly ICLC 1nilotinib 1liposomal doxorubicin 1lentiviral minigene vaccine of COVID-19 coronavirus 1envafolimab 1enasidenib 1TQ-B3525 1Sunitinib 1Nivolumab 1Methotrexate 1Metformin 1Ifosfamide 1HhAntag691 1Epirubicin 1Dacarbazine 1Cisplatin 1Chloroquine 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Chondrosarcoma × Chloroquine × Clear all
NCT02496741 2020-01-09

MACIST

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase 1/2 Completed
15 enrolled
CNSGastrointestinalSarcoma

Chondrosarcoma, Glioma, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡